Atyr_Logo.png
aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd.
February 06, 2023 08:00 ET | aTyr Pharma, Inc.
$10M milestone payment triggered by advancement of clinical program in Japan. Multiple centers in the U.S. and Japan are now open for enrollment. SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- aTyr...
Atyr_Logo.png
aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference
January 31, 2023 08:00 ET | aTyr Pharma, Inc.
 Symposia presentation to highlight significant advancements in understanding of efzofitimod’s MOA Poster presentation analyzing exposure-efficacy of efzofitimod further supports clinical...
Atyr_Logo.png
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 18, 2022 16:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
Atyr_Logo.png
aTyr Pharma to Present at BIO CEO & Investor Conference
February 07, 2022 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
 aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name
January 13, 2022 08:03 ET | aTyr Pharma, Inc.
SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis
January 06, 2022 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
Atyr_Logo.png
aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources
December 24, 2021 08:02 ET | aTyr Pharma, Inc.
SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma to Present at Antibody Engineering & Therapeutics Conference
December 10, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Dec. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923
November 30, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma to Present at Upcoming Investor Conferences in November
November 12, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...